<SEC-DOCUMENT>0001437749-12-008346.txt : 20120814
<SEC-HEADER>0001437749-12-008346.hdr.sgml : 20120814
<ACCEPTANCE-DATETIME>20120814060605
ACCESSION NUMBER:		0001437749-12-008346
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120813
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120814
DATE AS OF CHANGE:		20120814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		121029280

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geovax_8k-081312.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>geovax_8k-081312.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold"> SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="2" width="15%">
</div>

<div>&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of report (Date of earliest event reported):&#160;&#160;August 13, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="center" noshade size="2" width="15%">
</div>

<div>&#160;</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in Charter)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52091</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">87-0455038</font></div>
</td>
</tr><tr>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(State or other jurisdiction of</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">incorporation or organization)</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Commission File No.)</font></div>
</td>
<td align="left" valign="bottom" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="30%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(IRS Employee Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1900 Lake Park Drive</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite 380</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Smyrna, Georgia 30080</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of Principal Executive Offices)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(678) 384-7220</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Issuer Telephone number)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management.&#160;&#160;When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative if these terms and similar expressions as they relate to the registrant or the registrant's management identify forward looking statements.&#160;&#160;Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, operations and results of operations and any businesses that may be acquired by the registrant.&#160;&#160;Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 13, 2012 we issued a press release reporting our results of operations for the quarter ended June 30, 2012.&#160;&#160;A copy of the press release is attached to this Current Report.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>Exhibit 99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;August 14, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 216pt"></font>GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 216pt"></font>By:<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;/s/ Mark W. Reynolds</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 216pt"></font>&#160;&#160;&#160;&#160;&#160;Mark W. Reynolds</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 126pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 216pt"></font>&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-WEIGHT: bold">Exhibit 99.1<br>
</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><img src="logo.jpg" alt=""></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">GeoVax Reports 2012 Second Quarter Financial Results</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Three HIV/AIDS Vaccine Human Clinical Trials Advancing</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Phase 2a Trial Data to be Presented at AIDS Vaccine 2012 Conference on September 11</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Additional Clinical Trials Planned with Government Support</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Comments on FDA Approval of Gilead Science&#8217;s Truvada&#174;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Comments on Continued NIH Funding of Basic Research in HIV</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ATLANTA, Ga., August 13, 2012 </font>&#8211; GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, announced its financial results for the six months ended June 30, 2012 and provided a business update.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">David Dodd, GeoVax&#8217;s Chairman of the Board, remarked, &#8220;During the first half of 2012, GeoVax strengthened its financial position and made significant advances with our HIV/AIDS vaccine program.&#160;&#160;With the May initiation of a new Phase 1 trial of our second-generation HIV vaccine, GeoVax now has three ongoing clinical trial programs, two of which are fully funded by the NIH and are being conducted by the HIV Vaccine Trials Network (HVTN).&#160;&#160;We are particularly excited about the most recently initiated trial, as it utilizes granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant to boost the immune response.&#160;&#160;In preclinical studies, this version of our vaccine demonstrated an unprecedented 90% reduction in per-exposure risk of transmission for the E660 strain of SIV (simian HIV) and 72% reduction in per exposure risk of transmission for SIV251, the most virulent strain of SIV used in non-human primate models.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax&#8217;s President and CEO Robert McNally, PhD, further commented, &#8220;As we previously reported, the Phase 2a clinical trial of our HIV preventive vaccine recently completed patient enrollment and inoculations, and the HVTN is compiling the data for publication.&#160;&#160;We look forward to an oral presentation of data from this trial at the <font style="FONT-STYLE: italic; DISPLAY: inline">AIDS Vaccine 2012</font> conference on Tuesday, September 11, 2012 in Boston.&#160;&#160;The Protocol Chair, Dr. Paul Goepfert, Associate Professor of Medicine at the University of Alabama, Birmingham, will be presenting the data.&#160;&#160;Formal publication of the study results will follow at a later date.&#160;&#160;Planning is now underway with the HVTN for a Phase 2b efficacy trial commencing after the current Phase 1 trial testing the safety of the GM-CSF adjuvanted vaccine is completed.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. McNally continued, &#8220;Enrollment for a GeoVax-sponsored Phase 1/2 &#8216;treatment interruption&#8217; clinical trial for our therapeutic vaccine is currently underway. This trial is expected to be fully enrolled during 2012 and will continue generating data during 2013.&#160;&#160;We are also planning a Phase 1 trial to investigate the use of our vaccine in combination with standard-of-care drug therapy in HIV-positive young adults; we expect this trial to commence in early 2013 with sponsorship by the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT) and with financial support from the NIH.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comments on Continued NIH Funding of Basic Research in HIV</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Both Mr. Dodd and Dr. McNally commended the NIH, and in particular the National Institute of Allergy and Infectious Diseases (NIAID), for their commitment to finding a vaccine solution to HIV/AIDS.&#160;&#160;Dr. McNally stated, &#8220;The generous financial and operational support provided to GeoVax has allowed us to progress to where we are today&#8212;a company with the most advanced vaccine candidate for the version of the HIV virus affecting North America and the developed world. The recent award of $186 million over seven years for basic research and vaccine development to the Center for HIV/AIDS Vaccine Immunology (CHAVI), based at Duke University, attests to the commitment of the NIH for HIV vaccine development. Basic research funds will also go to Emory University and Scripps in an effort to further understand antibody and T cell antiviral function.&#160;&#160;We are pleased with the federal government&#8217;s broad-based approach to finding a solution, or combination of solutions, to the HIV epidemic.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MORE</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GeoVax, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Add 1</font><br>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comment on FDA Approval of Gilead Sciences&#8217; Truvada&#174;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. McNally also commented on the recent news related to the FDA approval of Gilead Sciences&#8217; antiviral medication, Truvada&#174;, for prevention of HIV. &#8220;The FDA&#8217;s approval of Truvada allows &#8220;treatment as prevention&#8221; to reduce transmission of HIV. However, given the challenges in getting people successfully medicated (only 28% of those currently infected in the US are estimated to be on successful drug treatment), by far the best solution still lies with a preventive vaccine.&#160;&#160;Truvada is a welcome addition to the arsenal to prevent the spread of HIV, but to truly turn the tide of the epidemic, the scientific community recognizes the need for an effective vaccine.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financial Review</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax reported a net loss of $497,763 ($0.03 per share) for the three months ended June 30, 2012, compared to $211,344 ($0.01 per share) for the same period in 2011. For the six months ended June 30, 2012, the Company&#8217;s net loss was $1,228,276 ($0.07 per share) as compared to $817,626 ($0.05 per share) in 2011.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reported revenues of $705,698 and $1,559,761 for the three-month and six-month periods of 2012, respectively, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes of Health (NIH). As of June 30, 2012, there is approximately $2.5 million in unused grant funds remaining and available for use.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development (R&amp;D) expenses were $712,416 and $1,784,770 for the three-month and six- month periods of 2012, respectively. R&amp;D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial of the Company&#8217;s therapeutic vaccine being sponsored by GeoVax. Costs associated with the Phase 2a clinical trial of GeoVax&#8217;s preventative HIV vaccine and the Phase 1 trial of the adjuvanted vaccine, being conducted by the HVTN, are funded directly by the NIH and are not reflected in GeoVax&#8217;s financial statements.&#160;&#160;General and administrative (G&amp;A) expenses were $492,316 and $1,005,134 for the three-month and six-month periods of 2012, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax reported cash balances of $1,817,014 at June 30, 20121. Summarized financial information is presented below. Further information concerning the Company&#8217;s financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.</font><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About GeoVax&#8217;s Technology</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax&#8217;s unique two-component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax&#8217;s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce noninfectious virus-like-particles. GeoVax&#8217;s vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. In GeoVax&#8217;s second-generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines&#8217; safety.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MORE</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GeoVax, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Add 2</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About HIV/AIDS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9&#189; minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to <font style="FONT-SIZE: 10pt">function against clade B.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For more information, please visit <font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.geovax.com</font>.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contact:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">IRG, LLC</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Erika Moran, Investor Relations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Janet Vasquez, Public Relations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(212) 825-3210</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MORE</font></div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Condensed Consolidated Statements of Operations Information</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(amounts in thousands, except per share data)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -10.5pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three Months Ended</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Six Months Ended</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grant Revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7.5pt"></font>706</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.5pt"></font>1,753</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7pt"></font>1,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>2,646</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">713</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,386</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,785</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,224</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">492</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">579</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,005</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,241</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,205</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,965</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,790</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,465</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7.5pt"></font>(498</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5pt"></font>(211</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 2.5pt"></font>(1,228</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>(818</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7.5pt"></font>(0.03</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5pt"></font>(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7pt"></font>(0.07</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>(0.05</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Condensed Balance Sheet Information</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(amounts in thousands)</font></div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30,</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"> </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec. 31,</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,168</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">293</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.05pt"></font>2,110</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 20.3pt"></font>1,418</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">139</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,290</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liabilities and stockholders&#8217; equity</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">380</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">941</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,910</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">704</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,290</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares Outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.35pt"></font>18,397</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 13.6pt"></font>16,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">###</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_[0U<4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``2`````$``0!(`````0`!.$))300-```````$````>#A"24T#\P``
M````"```````````.$))300*```````!```X0DE-)Q````````H``0``````
M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&
M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$))
M30/X``````!P``#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ`````#_____________________________`^@``#A"24T$`````````@`!
M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X
M0DE-!!0```````0````".$))300,``````NN`````0```'`````G```!4```
M,S````N2`!@``?_8_^``$$I&248``0(!`$@`2```_^X`#D%D;V)E`&2`````
M`?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.
M#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M_\``$0@`)P!P`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!````````
M``,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!
M!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($
M!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`
M]50LG*Q<2HW95S**AS9:X,;_`)SRUJX/ZT_XP\BO(MP.B$5MI<66YK@'$N:8
M<W&8[=7L;&WUK&V>I_@F?X5X^D?4#J/5BWJ/UDR;FEX!;2YQ?D1^;ZUMV]N/
M_P`2QO\`VS8K`Y?AB)Y9<`.P^:9^C`<]R,,<>,C<[0C]7H<W_&%]5L0$#)=D
MO!C;0QSI^%K_`$Z/_!55;]>\S+@])Z#F9=;N+'_HF_Y[67U_]-:+^F_5GZK=
M/NZDW#KJ9BMWFW;ZEQ,[6,9==OLW66%K&?I-BS\;"^N77*AG9/4OV+3=[\?"
MQZP][6'Z'VBZS8_U-OYG_0H_FD8C#5\/IVXLDNO]S$HG+=<7JWX8#_NLC/\`
M:G^,&]WZ'H^+BM/!OO#X_K>@]KD39_C%L$FWI5$]FMO<1_GJUTKHG6\'-;?D
M]:LZACEKFOQ[:FM&OT'L>USMKV.6T7L#@PN`<[Z+2=3\$R4P#48P/E&7_J1=
M&!(N1F#XD?\`<O-C`^O[OI=4PF>3:''_`*HA2&!]>Q_WJX;O(XQ_@]=(L#ZW
M6=0KZ4[J72;W-R.FO%UE3'2RRMI!R*;V?1_F_P!)_I$HS,I"-0%Z?)%,HB()
MN1K^LP%/U_9QD]+M_KUWM_\`/;UD==LZ_P!1MQ/JSU,XWKYUHNM;@N>`<6@.
MMM;:[)C8_(N;LH_XI=EA9E&=ATYM#IIR*VVL/\EPW>Y<U]5GMZEU3JGUJO<&
MT6O^QX#G$@#'J(W6#?\`FWVAO_7?53H2(XI&,1P;4*_6?HK9QN@)$\7<_H?I
M-BKK_6L*IC,OZM9%%+&AK6X5E.2&M`AK&U5&EWM_J*=?UZ^KV\59EEO3;R8]
M+-I?2?F\M=3_`."K<=DX[`2^UC0UN\DN`AA_PG]3^4DYF-ET[7M9?2_D$![#
M_P!4URCXH'YH5_=)_P"[XU]2&TK_`+P_[WA5C96+EU"[%N9?4>+*G![3_;87
M-15S=WU/^K^3:_)Z18[IF8W0W]/L]."1]"RAA]'9^\S8Q"HZUUOH>=3@?639
MDX>4\58G5ZF[!O)]E6=2/92]_P"^SV?\;^FMI/M@_(;/[DAPS_P?WE<9'S#3
M]X:Q?__0%U7H&5]5NMT9UU+K^E4Y++J[FC</3:]K_1N_T=[&^UOJ?H[UZGA9
MN)GXM>7AVMOQ[1N98TR"/^^N;^>QWT$9S6N:6N`+2((.H(*R/^;'3Z+G9/2W
M6=*O>9><0AM;S&W]+A6MMPG_`-;T/5_X13SRC*!QZ2CIQ?HR_O,./%[1EP:Q
MD;X>H_NM+_&'CW7?5FU]32]N-;5?;6)]U;'?I./W9]1RO9S<_K.#BW]"ZFW"
MHM_2NR&U-N<]I'LK:RW:UGN_G?\`"?F*S77U1K#5E''S*W#:YP:ZDD<$.J<<
MJNS=_7J6(/J7=BV/?T+J>3T>FPES\0!MU(<8EU5;W?H^$(F/"(F0!B28R(XX
M>K]Z/_H*2#9(B3Q`"0OAEZ?ZSG9N?]9>@=6;1D]5_:=;L'+R@Q]%=0W45OLK
M;^BW/_G&?Z15;.D?5JCHF'U+KE>5U;J?5VBPWT%[[@Y]?K%U3&V,J95BM]G_
M`'S9^C6[B?5'J#>KXW4^H]6/4CC,LK%5M#6@LM:YEC)99_+_`#F/3,^IW4,'
M=3T3K=_3\$N+F8CJV7MKDEQ92^X[V5[G?14ON0%5,`T.*4`<8E\WI],?^X8^
M"9NXDZGA$B)\/^-)PL;-ZMU3`Z3T#,R+\?'SLK)ILRK6FK(NQ<=C+:JW;R??
MD>K]GL_G/YK_``OZ7U;OUC^KW2_JU@#KG16?8[\5[&VTE[WUY-5CV56XM]=S
MW[MS7?Z^Q]>L[ZJ9.;@NQ.L]2LSK&6-OP\ME;<>^BQOYU=E3G-?_`&F?^B_2
MA1]3[[<JB_K?5;^K5XCA9CX[VMKJ#V_0LN967>N]G\I+W86")<,0290B)<.6
M_P"7!ZT^W*J,;)KAD2/U;S]W4,CHG2^J?5&B3F'(;C])!.KL?-.YL'V_S&ZU
MC[?]-8Q6>A?5SIG5<W-P^H!U^'T-S<'#P2XL:W:T.OSK&5%FZW-NWV[O^K_1
M>GU&7T#$RNN8?6K#^FPJWUAD2';OYISO_"^^_9_QW_!JKU3ZKG)Z@>J],SK>
ME=0>T,NMJ`>RUK1M;Z^/9['O8WZ#D/>B10/!*0XI3_UG\O\`IJ]J5V1Q")H1
M_J.)A="P>D?7VG#Q9.)=@VO;CO)>*VN?M?2W?N_06.;OVN_X14.LOL^K>??]
M7>F9M>-T_JY8\[IG!]5WIW[(]C*;V?S?^B_X'^D6]#@?4V[`ZFWJ[.I/R<]U
M=C,BS*9Z@>7AHJ>QM=E+JF4[&_HM[_9[/T2LX'U1PZL//IZE8>I9/57$YV38
MT-+A_@F55@N]!F/_`('9_-O_`.M^F?>@""9<?IC$BOFD#\_J_=0,<JH1X/43
MO^C^[I^\Z72NE872,"K`P:Q714('$N/YUEA$;K'_`)ZI_6#$_;&-^QV,+J[G
MUG*OX;576]ES@UWY^3;L].MC/YK?ZUOYGK%Z/T5W3<.K%LS<C-90T-K%I:T`
M#Z+?T+*WO;M_T]ERMY=N74UIQ:!D$SN:7BN--/<6N4%U.P>(W8D=-?WM68BX
M410JB/F?_]'U5)?*J22GZJ27RJDDI^H>I77T=.RK\9CK+ZJ;'TUL;N<YX:36
MQC/SW.>N=LO^M[675V.<VW&J<=]%;;&VNHHJ>[TO5HKWVYV5F?HZV,_[0V4U
M_P"%7@"2GP\%>KA_POP8<W%>G%_@W]=GZ#LR_K/L?LKO-]XVU,;7614Z]SK]
M7V^A2[]DX%-;&/?=Z&7U')LIW_Z&N_/^L]M59><K&=96(%.,U[C=7CT/]/\`
M2T6U4MRL_+M8]^3Z-'ZA^COI_2+P1)2Q]KKP?\W?_"8Y>[TXM_ZVW^"_1/3,
MGZP6]3R1DAX:*G;*W5[,=EK176VL.?5ZE_JV^M?3D8^=D?J_Z/)Q\6[T5`==
M^L1;18WI;R;&&UV,:WM=M].UU=9R=[J:+_7QG;ZK&?0R\*K^=]9?/*2;^JLW
MP["O\7U?+_Z.N_6T*N[-_P",_1#^K=>+"VNC>X4.>RP8U]8M>?58QC6V[_L#
ML=[*=[<OUOM;+?4J]%0MZM]9Z6/#,)MNXM]![J[20)R]OVD5?3LN9BX>^RNN
MBO$?G?I:_P!%^D^>DDOU/A7CO_+^7\VM_7?6OH_3'2LSJ.3D9C,VCT64O#:"
M&/:US9?_`(6[:Z]S=K-[ZZ*J/]#9D,_2+27RJDH,G#Q'AVT_)GQ\7".+?7\W
M_]DX0DE-!`8```````<`"`````$!`/_B#%A)0T-?4%)/1DE,10`!`0``#$A,
M:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%
M0R!S4D="``````````````````#VU@`!`````-,M2%`@(```````````````
M````````````````````````````````````````````````$6-P<G0```%0
M````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````%')865H`
M``(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4````<&1M
M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D```/X````
M%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\
M```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE
M=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````````````
M``````````````````````````````````````````````````````!865H@
M````````\U$``0````$6S%A96B``````````````````````6%E:(```````
M`&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B`````````DH```
M#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````
M```````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````````````
M`````````````````````````````````````&1E<V,`````````+DE%0R`V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````
M````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@````````````````````````````!D97-C`````````"Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````
M```````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0``````````````````````````````````=FEE=P``````$Z3^`!1?
M+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S
M``````````$````````````````````````"CP````)S:6<@`````$-25"!C
M=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/
M`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`
MP0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^
M`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!
MZ0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V
M`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#
MN@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A
M!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&
M2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2
M!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)
MI`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8
M"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-
MW@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#
M$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3
M`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@
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M-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\
M)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L
M0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'
MP$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<
M3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4
MCU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%
M6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEB
MG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ
M:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q
M\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG
M>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""
MDH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLP
MBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4
MBI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2
MGD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZG
MX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6
MLDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\
MF[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!
MQ[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2
MP=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<
MWJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J
M6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M
M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D
M0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`$0`P0,!$0`"$0$#$0'_W0`$`!G_Q`&B````!@(#`0``````
M```````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*
M"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S
M%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B
M\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7
MF)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ
M$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A
M8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U
M5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>G
MM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_
MV@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=0LADL=B:26ORM
M?18RAIUUSUN0JH*.DA4<EI:FI>.&-0!]21[O''),XCBC9I#P`!)/Y#JDDL<*
M&2615C'$D@`?F<=%:WW\\OA3UF\D.^/E=\?L!61%P^,F[7V95Y@-'^M?X+CL
MO698N/Z"$D^Q5M_(/.^Z4^@Y3W&13P(@D"_[T5"_SZ">X^X'(VT@_O#F[;HF
M'D;B(M_O(8M_+HH^\?YY/\L+9K/%-\E*?<-4I9?MMI===I9\,R_ZFOIMF+B"
MK6X;[C2?Z^Q?:>Q?NC=T_P"0PT2GSEE@3^1DU?RZ!UY[\^U5F#_R*5E8>44,
M\G\Q'I_GT73<7_"D'^7?A3(,92]][N*@Z&P/7."IHY2/II.YM\[?E4-_M2#_
M`%O8CM_NV^XLU#+)MT7^FG)/_5.-^@U<?>9]MX:^%'N4W^EMP/\`JY(G0*Y3
M_A3S\4HRXP7Q\^0^2`)"-E$Z]Q`<#\G['=V?T@_[$^SRW^ZYS=(`9^8-O3[!
M._\`UB'1#<?>KY/C)$'+VXO_`*8P)_UE;I`5W_"HKJ5'T8OXE]BUA8VC%=V3
M@,<[_P!/1!M/)V)_P)]F`^ZSNRC];G"U7_FQ*?\`"R]%[?>NV=C2#DR[;[9X
MA_@5NHD?_"G3&U0!QWP6WS6J;6*=PP\C^H\74D]^?=C]V"1?CY^M1_S8/^6<
M=:'WIHV_L_;Z[;_F^/\`)`>IL?\`PIA8G]WX#=B(O'*=M^0_X\-T_%]!_CS[
MH?NR#R]P[/\`YP_]=SU8?>B/G[<WO_.;_MW'3C#_`,*:MF06.<^%?:F+4?K:
M'L'&U6GFQL*K8V,!M8_4CVV?NPW;?V//=BQ_YIL/\$C=.#[TMFO]OR%?*/\`
MFJI_PQKTI,;_`,*?/BZ[A,W\=>_:!@0)4Q-1L#,.G];+6[CP&HC_`!*W]I9?
MNN\T4/TO,NW2?:)E_P`$;=*HOO4\JU`N^6-QC^PP-_AD7H9MN_\`"D?^7]F!
M&,OMSY%;1=K>1LUUYM6K@BO:]Y-O]A9F9U6_XCO_`(>RBX^[-[C0U,4NW2CY
M3.I_XW$O^'HYM_O/^VTU!+%N,1^<*,/^,2N?Y=%?_G"?S7NL.V?Y?6V<7\7]
MT[K"_)SL+-;$JLQD<'N'8^6.P>LXL#F.P%QPKX*2JJL;E\[GL1AY9H6>BK:=
MLG2%W,4\8$_L][2[KLWN'=2<U6D.K:[=)0H=)4\:XU+!J*DJ"J+)*`:,I$;4
M%0>@M[S>[^T[U[<6L?*=W/IW6Y>(L4>)_!M]+3Z0P5B&=HX25JK5D6IH1T=+
M^5+#\)?@[\>=J=';A[Q^/.T/E1D:.FW#\B</N+L/8NW^R*+?^;CCR;=?9V/,
M92CRC'K>BK(<.:*)FIX:VFJ90HGFG9@3[L'G?GCF*ZWVWV+<9>4P2MDRPRM"
MT*$KXR:5*_K,&D+\2&`K0+0<^T:\C<B<N6VPW._;;#S<0'O5::))A,X#>"^I
M@WZ*D1A.`(8TJS5NXPFX,#N6ACRFW,WB-P8R8`Q9'"9*BRM#*"+@QU=!-/3N
M".19CQ[@^>WN+:0Q7,#QRCR92I_80#U.L%Q;W48EMITDB/FK!A^T$CIW]L]/
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__T-_CW[KW6*::&FAEJ*B6*"G@BDFG
MGFD6*&&&)2\LLLKE4CBC1268D``7/O:JS,%4$L30`<2>M,RJI9B`H%23P`ZJ
MS^2?\YW^7U\9I:_$Y[NFC[,WA0>9)=E]*TT?8>3%3!Q)1U.>HZNDV+C*R.3T
MO#59:&=&O=.#[E7EKV5]P^9ECG@V4VMDV1+<GP5(]0K`RL/0K&0?7J)N9_>[
MVYY7:2"??!=WRX,5J/'8'T+*1$I]0T@(].J-N\_^%0N^*YZW'?&[XV;:V]!I
M>.AW/W#N+);IKIM9<+.^S]HMM>DQL\:Z2%.7KT+7O<?6<=C^Z_MT81^8^9Y9
M9,=EM&$7[/$EUL?RC7J"=^^]1N4A=.6N5HH4S22YD+M]OAQ:%'V&5NB+4?\`
M,)_G<?.?)3XWIS<'=>2QE1*]*U)\>^NX]GX/"L9&#+6[XVI@J7*8Q$9M/DR&
M8]-N6^OL>O[>>R/(L8DWFTL(W];V<RN?LB9J'[%BZC]/<;WSY]D,6RWE_(GI
M90")!]LJK4?:TOY]"YM?^15_-;^2DU)FOD-V+BMH1U!6IJ9N[^Y\WV-NF-6M
M('CI-KMV#&]7S?145M,RG]1!]E%U[[>U'+2>!R_M[S%<`6MK'`G^]N(C3YA#
MT<VGL'[M\SN)^8MP2`-DFZNI+A_]X0RBOR+CH]W6O_"7/84$4$W<OROWAGYG
ML:G'=;[!Q.V%@^EXZ?.[IS>[_N;?AWQL5_KH_'L![I]Z6_D+KM'*<*CR:>9Y
M#^:QB,?\:/0^VK[J6WQA&WCFZ9F\UMX$C'Y-(TI_XR.CW;%_X3O_`,MG:4=.
M,]M#M+LR6$QLTV]>T<O0&9TL29(^O*;8D>AV'*VM;CV`K_[Q/N5>!A;W=I:J
M?]]6Z$C\Y?%/\^I`L/NX>V5F0;BTO+IA_OVX<`_E%X0_ET;K:O\`*8_EO[-C
M2+$_#_J"M2.VD;LQ61WX3;Z>1M\Y/<32_P#(1-_81N_=WW+O:B;G.]`_H.(O
M^K83H86?L][8V)!@Y*L21YNAE/[92_1BMO?$7XH[26-=K?&3X^[=$(`C;"]-
M]=XV10OT_=I-NQ2$C^I-_8:N.;N:[LDW7,VX25_BN)F_POT)K?D_E*T`%KRO
MMT=/X;:%?\"="YC=A[&PRJF(V9M3%(@`1,;MW$4*J!]`JTM'$%`_P]E,M_?3
M&LU[*Y_I.Q_PGHXBV^P@`$-E"@_HHH_P#I310PPKIABBB4<!8HUC4#^EE`'M
M*69LL23TJ"A>``ZR^]=;ZQR112C3+''*O^ID17'^V8$>]@D9!H>M$`X(!'2:
MR.Q]E9A63+[/VME%>X=<CM_$URL&%B&%322AKCZW]J8[Z]AS#>2J?D[#_`>D
MTEC8S8FLXG'S13_A'03Y_P")GQ8W6LB[G^-70.XA*")#F^G>O,HS:N#=ZW;L
MS7/];W]FT'-G--K3Z;F6_CI_#<2K_@<=%%QRCRI=U^JY9V^2O\5O"W^%#UJ.
M[%Z]V)_,&_G9X+KKJS9FV-N?$7X=92M_@NS]G8/'8?8%'L7IW=E7F\PU!@L9
M34^!FQG;/?.XYY9BD<;U6.S!=M?BO[R\OMPOO;OV0GW+=;R63G#>D&J21F:4
MRW,85:LQ+5M[-`!GM<`8KUAU8;=M_N/[Z6^V[3911\F[(YTQQHJPB*UD+-15
M`4"XO')..Y#7-.KRNX_Y#/\`+V[FW5NS?.4VMVCM/>.^-PYO=FY]Q;4[4W#4
MUV4W'N/(U.6S66ECWP-Z4*5-?DJN69PD*IK<V4#CW!NR^_WN+L=I:6$%W:RV
M<$:QHCV\8"HBA54&/PVH%`'&N.IWWS[O?MMOMW>7\]G=Q7D\KR.\=Q(2SNQ9
MF(E,BU+$GA3Y=$ESO_";;;^SZN?-?&;YM=V]1YM6,U)49S$4F9JS*I'C23.[
M%SO6=73Z5X$BT\C+8>D^QO!]Y>YO$6'F?D:PO(C\14D8_P!+,LX_*HZ`MQ]V
M&VLW:;E;GO<+*4974H.?]-"T#?GGI.O\//\`A09\8RD_2OS"V]\CMOX]+4VW
MMX;OI=R9ZOIXE9%I*FF[[VY+1T(,:C3]KGM8/T<'VI'.7W=^:!HWODR7;)SQ
M>-"J@^NJU<5_.'\NDYY+^\=RKW['SK%ND`&$ED#-0>5+I#_*;\^F[_AZ#^9-
M\49(J3YX_P`OJODV_2.8:_?^S<=NK8..$2Z@U4NXY(^QNNL_61FUXJ2JH8G'
M(9!;VY_K*>V?-H9^0?<11<'(BD9)2/EI_0G7\T<_;TU_KX>Z'*!5/<#VX<VP
MP9HEDB!^>K]>!OR=!]G5B_QR_GL_R]_D!+08?)]D9+HG=U;XXQM_N_%Q[6Q_
MW#%494WOCZS,[&A@\C`(U9D**1P;^,&X$<<R>PON)R\))8ML6_M%J=5JVMJ#
MS,1"S?L1A\^I*Y9^\![;\QF*&7=&V^[:@TW2^&I)\A,"T/[74_+JWW#YC$;A
MQ=#F\!E<;G,+E*>.LQN7P]=2Y+%Y&DE&J*JH:^BEFI*NGE'*O&[*P^A]PY-#
M-;RR07$3),IHRL"K`^A!H0?D>IGAFAN8HY[>59('%592&4CU!%01\QTY>V^G
M>O>_=>Z__]':Y_F-_P`U#H?^7CM:*DW(&["[OW'BI,AL;IS!U\-)D*FE9Y:>
MGW#O/+&*L7:&TGJH7CCG:">JK)(W6FIY5BGD@E'VW]JM^]Q+II+<BVV&)J2W
M+@D`\=$2X\22F=((50079:BL5>Y?NSL'MQ:I'<`W6_RK6*V0@,1P\25L^%%4
M$:B"S$$(K48C1]^97\U#YB_-ROR5%V7V16[<ZVJYY?LNG>OI*O;'7E-2,\A@
MI\IC:>JEKMWU$*R<3YBHKY58GQF-2$&;W)WM?R;R1'&VT;6LFY`9N9@))R?/
M22-,0/I$J_,DYZP6YT]T^=.>I)5WC=6CVPG%M"3'`!Y!@#JE(]96;Y`#'0S_
M``*_DN?*WYQTV+WY)1P]+=&9'Q5$':N_J&K>7<M$[.LD_7VT8Y*7*[O52HM5
M/)0XI_4JUIE1H_9/S][S<J<C/-922F^W]>-O$P[#_P`.E-5C^:@/)ZH./1W[
M?>RG-O/:0WT<2V'+S<+B93WBO^@1"C2#T8E(SY.>'6V9\6/Y&'P'^-4&-R>9
MZ[/?^_:3PS3;N[J6EW'BUJXW\Q;%]?1PP[(I*6.<!H?NZ3(5<6D?Y2QN3B;S
M5[[<_<RF6&WW`;=MS5'AVU4:G]*:IE8^M&53_".LN>4_83V^Y8$4UQMQW+<E
MH?%NJ.M1YK#01*/2JLP_B/5N<,&W-FX`QT\.$VKM;;N-FE,<,=#@\!@L1CX7
MJ*B4H@I<=B\;14\;.[>B*-%)-@"?<0LUS>W%69Y;J1O.K.S'`]2Q)QYD]3&J
MVUE;T58X;2-3PHJ(HR?0*`,G@!UJ=?)K^;C\R?G+WODOBE_*AVUFX-O4,]70
M97M[%8ZA3=>YJ&CJXZ2OW9#N#<2Q8/J;KM96"T];4&#*3ZXF\]-+,*(9;<K^
MT/)G(>PQ<V>[5Q&;HT(MV+>'&2*B(HG?<3TRR+^FF00P!;K$#FGWCYUY^W^7
ME'VAMI!:BH-RH7Q)%!H90[]EM!7"NWZCX(*DA.F&B_D5_P`T3?,,6YNS_GU2
M4V[\@355M/4]I=V[SK*668EVBJ,W54-$)*B,FS"'R0@\([+8^U#>_/M98$VF
MV>WQ:S7`(@M(P1\EHYI]IKZ])U]@/=?<`+O=/<0+>MD@W%Y*03Y%ZH*_8*>G
M4D_R&OYE.`+YK;'S_H9,[BE:OPJ1]A=V86:;(T@\]'$,G!1U#XUI*B-5$RJ_
MC)U6X]Z7W_\`;*<K#=^W;?3.:/\`HVC=IPV-(KCRJ*^HZ\WW>O=&`--9^Y"_
M4H*I^M>+W#*YU&F:9H:>AZVN>K(MY0=8=<0]BOY.P8=A[0BWU(9*:;R;RCV_
MCTW._FHE2CEUYL3G5"!$WU0:;>\2MT-FVY[BVW"FWF>3PN(_3UG1QS\-..?7
MK+[:1>KM>VKN1KN(MX_%X?VF@:^&/BKPQZ=+SV@Z,.O>_=>Z][]U[J#D\9C\
MUC:_#Y:C@R&+RE'4X_(T-5&LM-6459"\%333QMZ7BFAD*L/R#[<BEDADCFB<
MK*A!!'$$9!'V'IN6*.>*2&9`T3J00>!!P0?M'6HOU?O+?O\`*T_G6'X_[HWY
MO>L^+/R/FH<3L;';OW=N#/X7%;;[/J6'6^0I_P".U]:OWNPNRZ!]MR9&HD:H
M&,CJYI)#YFOE]NUK8^ZWLB.8+;;[<<U[8"TK1Q(CL\`_7!\-02)H&$X7AK`H
M,=8<;3=[A[2^^;<O76XW+<I;H0L0EE=T5)S^@1XC$`PS@P%N/AFI)KUM[>\/
M>LR^J\OYIWRK3X>_"+N;M3'Y`4&^<MAFZXZN9)5BJ_\`2%ON&IQ.*R-!K95E
MJMJ8W[S-Z"?7'C''-[&1/:KE3^N//&R[3+'JL$?QI_3P8J,P/^G.F/[7'4<>
M['-O]2^1-[W>*33N#IX-OZ^--V(1_I!JD^Q#U73_`,)ROBF_4GQ0W)\B]S8X
MP;T^2VXS58>2IA9*NDZOV-59'#X!0LUYJ<Y[<\V5K&*V2JHQ0R>H*A]R/]Y#
MFO\`>_-MMRW;2?XEMD=&`X?42@,^.'8GAQ_(AQZ]1I]VCE']S\H7/,US'_CN
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M%]J_=M(]JY_V..PWQAI2<M1:GAHN@`\?EV3AHN`+'J!;[VV]V/:"27=O;W?9
M=PV%3J>`+5M(X^):DE),5J]N5EXD*O5K7\L[^<UU%\ZIZ;J?L#%4G2_R<IJ>
MI+[#J:R5]K[^&.A>;(5G7>3R#+6_Q&F@A>>HPE66K:>!6>&:MCBJ)8HE]SO9
M;=^0U?=]OF-[RN2/U0*20ZCVB91BAP%E7L8X(0D*9=]K?>[9N?V39]QA6QYJ
M`/Z1-8YM/Q&!CG4*$M$_>H!(+@,PNH]PGU.77__2J2^3G>6^_DEWYVKW9V14
M5\F[.P-Y9G-UE%D)9I),!1O5/!B-K4RS@24^-VKB(8,=2PD#PTU+&G]GWU6Y
M;V6PY<V':-CVU%%E;0*H(IWFE7D-.+2,2Y/F6^SKDUS+OE_S+S!O&^[F[&]N
M9W8@_@%2$C%>"Q*`@'D%]:]6Z?R%_P"7KLCYD=[;P[.[EQ4&XNG_`(]P;;R5
M3LVN028S?>_-S3Y1MK8;-P-Z:_:^*IMOUE;D*8^BID2FIY5DIYYT:)/??W"O
MN2]@LMMV64Q[UN)<"0?%%"E!(R'RD8L$1N*C6PHP4B7O8+VZL>=N8;W<][B$
MNR;:$8Q'X9IG+&-7'G&@0NZ\&.A352P._52TM+0TM-145-!1T='!#2TE)2PQ
MT]+2TM/&L5/34U/$J10001(%1%`55````]X#,S.S.[$N34DY))XDGS)ZZ"HB
MQJJ(H"`4`&``.``\@.L_NO5NJ0?^%`W?^<Z1_E\;BV_MBOGQN:[[WUMWIF:L
MI'*54.U\GC<]NO=\"L`5--F\)M-\54J>'I<C(OU-Q./W?.7X-[]P[6XNHP\-
MA`]R`<CQ%*I%6O\`"\@<?-1U!/WB>8;C8O;FZMK64I-N%PEL2#0B-@TDM"/X
MDC*'Y.>A-_DI_$K:/QA^"W4^=H\13)V/W]M?;_<G8^XW@093)+N['C,[(P+S
ML&GAQ>UMHY*GB2FUF):Z:KG4*U2_LK][.;KOFCGO=H&F)VO;Y7MH$K@>&VF1
MZ<-4D@9BW'3I7@HZ-/8[D^TY5Y!VBX6$#=-QB2YG>G<?$75$E>.F.-E4+PU%
MVXL>CM]C_,WXC=/[IK-C=J?)OH?KO>>.BIILCM3>7:NR=O;BQT=9"E32-7X;
M)YFFR%$:JFD66,2QH7B=7`*LI('V[DSF[=[1+_:^6;^XLF)"R1P2.AI@T95(
M-#@T.#CCT.]RYUY/V>[>PW7FC;[:^4`M')/$CK45%59@149%1D9X=(F'^8O\
M!:B:*GA^:'Q?>:>1(HD'>'70+R2,$106W"%!9B!R;>UI]NN?@"?ZF;I0#_E&
MF_Z`Z0CW(]OB0!SMM52?^4J'_H/I5_*GYA=%_#KI.N[X[DW4E)LY31TFVJ3!
M?;Y?/;]S>4I9:S#[?V50K4PP9C(9.D@>=9#-'2PTL<E1--%!&\BIN5.3M^YR
MWN/8-EM*WF2Y>JI$BFC/*:=JJ2`<%BQ"J"Q`Z5<V\Z;!R5L4G,&]W=++`0)1
MGF=A54B6O<S`$C(4*"S$*"1KHO\`\*!OFGVA593=OQP_EY9C=G4>+K:B&3-O
M@NUNQ:D4M)):23*;EV/B,3MO!5;1>J2%XIUIR;%Y`-1R/_X'OD?:E@L^9?<9
M8MW<#M#6\(J>&E)G,C#T)TU]!UC2?O%<];LT][RQ[;--LR'XBMQ,:#CJ>&,1
MJ?4#5I]3U9C_`"Y/YS_2WSLW,W3FY]IY#HKY#P4M?4TW7^<RJ9C!;Q3#PR39
MA-F;ADH<1539K&4]/+45&*JZ2&ICIHWDA>I2&H>&,?<GV5WKD.U&\VMXM_RX
M2`9572\6H]OBI5AI;`61&9"2`=)*@RE[9^]^Q\_W1V6[LVV_F0`D1,VI)=([
M_">BDLM"6C=5<`$C4`Q!E/Y@G\R3H?\`EX[#Q>X.RSD-V[^W=]RG7W4VV)Z2
M/<VY_M&2.KRM;556JFVYM:@FE1)ZZ9)79R4IX*F16C4,^WGMIO\`[BW\MOMF
MF';H:>-<2`Z$U<%`&7D:A*HOD*L5&>A1[C>Y_+_MOM\-QNFJ;<9Z^#;QD:Y-
M/Q,2<1QK4!G;S-%#-CJBC_H('^=2XK_2TW\NR<="^+^)_P!YOX5V\,5_![>3
MS?Z63@?[F:/$?^!'\-\?YT?CW/'_``/?()E_=`]Q_P#D04IX=;:NKT\#Q/$X
M_AUZNH!_X(KW!\']\'VU_P"0[6OB4NJ:?7Q_"\/A^+1IZ#;^97WITA_-A^$.
M)^7O0-+EMJ=]?#7<-%-VQUCEIHAOC;_6>_*ZCQ=9F*&MQ31'<VW<1NZCH*NB
MR4*Q_94S5[3PTLK%"9^V>P;[[2\\R\G[^R3<O[U&1;S+7PGGA!(0J<I(\9>-
MXVR2R:2RT/17[H<P;![O<B1<Y\O*\',.QR`W$#4\6.WF(!<,N)(TD"2)(N`%
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M>+3@LTXJ6-/]\6P,GR\0]&![O_GA[,Z'SFV_AO\`RW?C[5?(^LZFP6,ZUPV;
MIH=P9G:;0['QL&"@Q.Q]K;(I9-S=@45#2X]4DR<=30P5#HTE.*F!TJ'(-B]B
M[S?K>YYS]R^8AMJ7;M.R=BR?JG7JEDE(CA+5)$='<"FH*>WH0[_[\V>P7-KR
M3[8\N'<Y+1%@5^]HSX0":88X@9)@M`#)5$)KI+#NZ!J;_A0K\K>II,SL[Y8_
M#J'I3>N6V[EJS8.>K=E=E[=H:3.TD2MASN+K;?.:QF=W)M.NKF2GKJO'9RCJ
M***7S1153J*=S@?=XY2W9(;[E+G,WUDDBB5!)`Q*DT;1-$&6.0"K*)(BK$:2
M5KJ!-_P1O-^T//8<W\E"POGB8Q.8YU`<"JZX)2K21DT5FCE#(#J`:FDV0?`'
M^81\J_YB7Q$[5[/ZRVAT7L+Y!=8;[K=JXO![JQF]\MU+O]!MW$;@QE+.*+>6
M.W7LBLJC7RTK5'WF5AB>..8QE9&BBC;W"]O.4O;KF_:-LW&]O[CER[MQ(70Q
M+<1=[(QH8VCD`TZ@M$)!I4$5,F>W?N-S?[D<F[QNFVV.WVW,MI<&,(XE:VF_
M321142+)$3JTEJR`$:J$&@37\MS^<#NKY)=[]A?$;Y>]<[6Z#^2FVLIE*':F
M!PJ9K%8C<]?MLU<6[-ES4&Y<WGZRDWGA4HGJX!%6309&C2<QB,TZFI5>Y?LY
M:<L[!MW-_)VYR[ARS*BF1VTED#T\.4%%4&)ZZ350T;T5OBPD]L/>>\YHY@W+
MD[G/:X=NYGB=A&B:@KF/^TB(=F(E2FM:,5D2K+33E9?S7/YM4OP3RO77372.
MSMO=O?);L2II*Y=FYA,UD\7M7;%;4-C\/+E,1M>NQV=RFY=XY;]G%T$%1'(8
MH99I.&IHZE%[3>T2\^1;EO6^WLMGRQ;`CQ%TAI)`-3:6<%5CB7NE<@@551FI
M5=[N^\+<@2[;LFPV,5[S1<D-X3:BL<9.E=2QD,TDK]L2`@FA8XTAK)OB_7?)
MS-=5X'<GROI.K=O=H[AHJ;*UVQ.J,/N*CPNQH:N/SQ;?RN9W'N[=4VX-Q4D4
MBK72TQAHHJA7C@,\:BHDC3FF/E>#=KBVY2DNY=IC8JLMPR:I:8UJB(@1#^$'
M4Q%"VD]HD_E23FJ?:+:ZYOCM(MWE4,T-NKZ(JYT,[R.7<?B(TJ#4+J`U$QGL
M-]"7K5+_`)^_P5P'5E!MK^9%\=(O]&/9^R^P]J_Z5IMI:,*N1R>2RL(V=VMC
MEI%CCH-Z8[=\=+2ULL:WR+UD-2]IH9GJ,L?N_P#/EQNLEQ[:\QGZK:YK:3Z<
M2=U%"GQ;8UXQ/'J9`?[,J0N&`7$;[PW(%OM,=M[G<M#Z3=8+F/Z@Q]H+%@(K
MD4I259-*N1_:!@6RI+%Y_P"@BSY=_P#>.M%_YX,O_P#4WLZ_X';E#_IHV_WH
M=$?_``2'.'_3-+_O+=?_TS"_SI_Y.'8?6/8F_/EK\:ML9'>W3N^<QE=Y]E;)
MV_1S5^XNI]R9:IER6X\O38BE22HK^NLA7S2U:S4R$88.\,T<5)%%,V;WLO[Q
M;;N^V[?RES+=K!OMNBQ0RN0$N(U`5%+'"SJH"T8TE`!!UU!P7][?9G<]GW/<
M><.6+1KC8;AVEGB05>VD8EI&"#+0,Q+U45B)(8:*,`R_X3X_/#8?Q<[UWWT?
MW#F:+:FP?D3'M>GPV\<Q/%1XC:W9&U9<O#MZFSE9.8XL9A-UT6XJFEEJY6\=
M/614AD\<#3S1F?W@N0MPYJV&QWK:(&EW/;/$+1`59X'TERB\6>,J&TC)0O2I
M`!+/N[^X&V\J;_?[)O%PL6V;IX825C1$GCU!`[<%216*ZC@.$K0$D;WX((!!
M!!`((-P0>001]0?>!W6??7?OW7NJ#/\`A1KU!G.Q_@%2[SP-+45;])=Q;.W_
M`)V*FB:=UVQE<7N+8%;4&&-7D,=)F-W4$DC`6BA5W:R*Q$_?=OWB';?<$V4S
MA?KK.2)*^<BE)E'^V$;`>I('6/?WEMFGW/V[6]@0M]#>Q2O3RC8/"Q_VID4G
MT`)Z.A_*2^06U_D5_+_^.6X,#DJ:KR_7_7VW>F]\X^)T-9A=W]787'[6J(,C
M`C-]K+F</14>5@4GFDR$3?4D`%>[G+MSRW[@<QVT\9$%Q</<1,>#Q3L9`1ZZ
M260^C*P\NAQ[/\QVW,WMYRU=02`SV]NEM,HXI+`HC(/IJ`5QZJZGSZ)1VI_P
MGO\`C1W[VUVUW=V_W#WI-O?MCL_?F_ZRCV1EME87;F$Q^Z-RY'+8;;]#3[@V
M/NG*5!PN+J8J=YWJ525T)2*--*@;[7]X;FC8=GV;8MHVBP%A9VD4(,JR,[%%
M`9R5E11J:I`"X'$DU)`NZ_=SY6W_`'G>M^WC>+\W][=RS,(FB5%#L2J`-$['
M2M`26R1@`4'5.?\`-[_DY_&[X!_&?:G=/3^^^Y]P[FS'<>V^OJO'=@YK9F3P
MHP^9VGOG/3U=/'M[9&V*Z')0UFV(%1FF>+QR2`IJTLLQ>T'O'S+S_P`SW.R[
MQ96<=LEF\P:%9%;4CQJ`2TCBA#FN*U`SU#/O)[,<L>WO*UKO>SWU[+<R7J0E
M9FC9=+QRL2`L2&H*"F2*$XZ3W>^+J/D]W5_(Y^'._P#-Y&GZ@R/Q!^)N5RE'
M]_/325T_9D\N/WH]#4*ZF+(Y3;>QZ#&4<UW:">+TCZJ57+TJ\K[%[Z\Y;=`A
MWA-WO@II6@@H8P1_"LDS2$<#05X=)>8X6YJW_P!A>2MQG<;,^SV!85I4SU$M
M#_$T<*Q*>(J:<>MJGY>?,#XX_P`KGX^[*S^Y]FY:@V-#EL5UEUIUEU-M_#QS
M^2#%UM?'18RAK,A@L%B,-B<5C)))I9)T]1556220`XJ<G\F\R^Z?,-];VMXC
M7VAIYYYW8BFH+5B`[LS,P``!^=`.LLN<^=.6?:CEVPN;NR=;#6L$$%NBUKI+
M44$HBJJJ222/05)ZTVOG)\_/C_\`(OYG_'GY9_$/JCLCI[M_;&Z\'E.QJK<.
M/VQC(]\[BVWN7!9'9>>BI=FY[--D<Y4TRU5#EI*D*:ZDCI(V$@62^9G(GM_S
M'RYR7S'RCS?N=O>[/+!((0AD/A(T;B5"9$2B`Z9(P,(P8XKUA5S[[A\M\R\[
M<M<X<F[7<6.\Q3QF8N(U\5UD0Q.!&[U<@O'(30NI49IU97BNO]O?./\`X41]
MK[>[[IH=T;%Z`Q63K-J[!ST<=7@,EC^JL1MS$[<V]/05`,=7A:G=VY9]QU%(
MX>"K=ITE1X)I$,:37]QR)]W/9[GE]S%?[BRB25,,IN&E+L&&0WAQ+"K#*C((
M(!ZDZ';[;GW[R>\VO,*"7;]M5C'"^486Z1"-2IP5\65IF7@QPP()'6W@:2E-
M*:$TU.:$T_VAHS#']J:7Q^'[8T^GP_;^'T:+:=/%K>\/];Z_$U'76M:YKZU]
M?GUF3H31X>D>'2E*8IPI3T^76F]V!T9UU\9?Y]V(Z1ZXPE'2=(_+C8^0VEVA
MU3BE%'MT;,[\V1N3;N^-GK1TFA:+!IN3&)N"EI8PD-$5ITB5888U&9NW[WN/
M-/W?[C?=SN&.^;/.)()VR_B6DL312:CDOHD,+-Q;B222>L*=QV+;>5?O"V^P
M;7;JNQ;S`8Y[=<)X=Y%*LL>D8"^)&)E7@I-%```Z>/Y4WR#3^6!\C?GQ\)OD
M+FI*39O7.+W[W%M>MJW@HOXME>J,%-EZF;!44DB>3(]N]3_99*CBL7D&,IX5
M'DE"LQ[L\O?ZZ/+?('/'+L`-]<O%;R*,Z1</I`:GE;W'B(Q\@]3@=/\`M%S$
M/:KF;W"Y$YDG*V-JDMS&2::C;IJ)6N*W%MX;J/,I09/1)?C=#VKO?HG^:?\`
MS9MTK,-\5>"SO5W7F9B^X8XC>WR)WEMW;G:.<VK6?M5>(J>O>M-[)CL=+$P$
M%-F2$T-`ND;\RMM-CO\`[4>T=J0=O$J3S+_%%9H[0(X\Q--&TC@\2HKQZ`O+
M"[O?\O\`NW[P751N)BD@A?\`AEO)$6=D/D8()%C0C@&-.'6P)_PGJ^.G6?7'
MP2VEWIAL5BJWM'OS,;UR.\]W^&&HS,&&VGOG/;-P>S(*\KYZ3#T/]VFKY*=2
M`];62,^H)%HQ[^\/S+NFZ<^7FQ3S.-KV]8Q''7M+R1K(\I'FS%](8\%4`4S7
M(K[N7+&U;5R!9[]!"AW7<7D:22G<$CE>-(0?)5":BHXNQ)KBA^_YDOQRZR^2
M_P`->]]G]DXC%U#;<ZWWIOS9>Y:V"'[[8^]=G[;R6=P>Y,9D&45&/CCJ:`0U
MRQO&*K'RST[G1(WN/_;7F3<^6.<]AO=ME8"2YCBE0$Z98I'"NC#@:@U6OPN%
M89`ZD/W-Y9VKFGDK?['<X5/AVTDL3D#5%+&C.DBGB*$4:GQ(64X)ZJ"_X3!+
MH^+GR)0&^CORG6_]=.P]OB_^QM[F/[T8T\T\MKZ;>W_5^7J&/NJ-JY4YF;UW
M%3_V;Q=)3_A0U\5-C[(Q&P_YB'6V^<;U%\@]F[TV9MJK-)7/A\WV?744ZU&S
M\[MAZ1#++V-U]%B_,TQ"F;"4I+RJ:"FBE4_=WYLO[V7</;K<K%KSEZ:"5Q4:
ME@!%)4DKCP9JTIY2D%1WL0E^\=RC86,6W>Y&V7ZV?,4$\49H=+3D&L3QTSX\
M-*U_%"&#'L4$OO\`(<ZHP/S4^47>'SW^2O96,[2^0.Q=R4-;@-C940?Q;'9W
M/T`CI.V*[$+24N,APFW:*E&)VW3T:M38V>G9O%3-2XYF$'OQN]QR5RIL7(/+
M.VO:\O7$;!Y5^%D1JFW#5+%G8^+.S&KAE%6#/T'O8'9[?G?FW?O<'FC=$N^8
MK:52D34U*[K07)6@4(BCPH%4:4(8T4JG6XM[PXZS0ZXLRHK.[*J*I9F8A555
M%V9F-@%`')]^XX''KW#)X=5>?*#8%3_,:DPOQRP--5T_Q*PV]<%NSY"=O$RT
ME'VI+L;,Q97"])]+S`)/N&GJ=R4,51N#=-,R8W%BC2EHIJRM:JBHY4Y4W)/;
M;ZCF6<AN;W@>.SM^)M_%72UU<_P%4)$$![W9O$D"1A?$BCF[;']S/I^6(`R\
MG)<))>W'`7`B;4MI;?QAG`,\X[$5?#C+R,WAGQ_T&=,_\^JZ_P#_`$$L)_\`
M47N/_P!^;S_T=;C_`)R-_GZD+]Q;+_T:;?\`YQK_`)NO_]3?X]^Z]U3G\S/Y
M'_PL^7%5E=W8[;M3T)VQD6EJI=^=44M#08O+9*1C(:S=6P95BVWF))9F:2>>
MC_AF0J9&U2U3'W,W)?OGSMR@L%G+<#<-H2@$5P264#RCF'ZB4\@2Z#R3J%>=
MO8?D?G%Y[V*V;;MX>I,MN%"N3YRPD>&]?,@(Y\WZ+/TGUU_.!_EKT5#L>GQN
MU?YBOQ?P*QTV)Q6(W,^U>\=DX&%HXDBVY'NUGK9:2BIE/@PB3;CA1%2&FDI$
M!/L4[UN/LS[FN]\\\W+7-4AJS-'XEI*YR3)X7`D\9`L1/%E<]!/9-N]ZO:Y$
ML4@AYGY3CPJ))X=W$@P!'XIR`.$9>4#@K(.K(>H_YF7Q8[(R]!LC>FX]P?&G
MM^K1%EZ9^4>VZ_I'?:5;.(31XN3=PI=K;JF:>ZHN)R5;(PL2BZE!C/>?;#FO
M:X7OK*WBW/9QD7-C(MU%3U;PZR1XX^*B4ZE#9?=/E+=9DL;VYEVO>3@VU_&U
MK+7T7Q:1R9X>$[UZ.QO+9^T>S=E;EV+O/#X[=>Q]][<RFVMRX.O45.+S^V]P
MX^;'Y.@G\;J7I:_'U3+J1@P#:E8&Q]@>RO+S:[VVO[*9HKZ"171AAD=#52/F
M"/\`/T.[VSL]TL;JPO85FL+B)D=3E71P0P/R(/\`FZTZM^?&O^8-_(U[OWAW
M!\2*#+]X_$;>-:E7N##S8G(;IQ<6WZ6IFGHL-VUMS!/393;FXMM05<L5%NBA
M$-)(KW+QBHJ,<,R[#F7V\]]MCLMFYNDCL>;X113J6-M9'<]L[]CI(15[9\@_
M#6@?K"O<.6/<;V$WZ]WKD^.2_P"39C5ETM(N@'M2Y1.])(P:)<H*$?$14IT:
MG:?_``J%Z>J,-22;Y^*O9^&W#X8Q74FU=Y[=W'A_N`BB9Z6NRV+VO6")I+E5
M:G)4<%F^I"ES]UC>_%;Z#FJU>V/`R0RHU/*H7Q%_,-3H66OWK]C,2B_Y3NDN
M0.X1S1.M?.A?PV_(KU77_-?_`)RO4?\`,%^-VVNE-A=/=F;%S>$[<VYV)-F-
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M\\<F.TO,6U[9;#3$07=$574Q4P98)0Q"<6#.N6`4HRH_GI_''N'`=;8/^89\
M)MS[[[.Z4RV2J9\#BJ+;6;ZXRN]I\/+MS([CSO6G83XP8K*4M+-,(,?529.&
MCJ)6E5A(L7B,%]A>9MGGW2?VZYVC@VJ^0#4WB"81!@X19X`X=2P%7706``(I
M6I<WO_RMO4&U0>Y'(TEQNU@[-I7PVA,I4QEV@G*%&"DT1M84DD&H%%[M#^=;
M_*/VUNC`9[!?RX'V=F,5E:&MQVZMO]$_'2BS>WZJ"HC>++XJKH,E0UM/74##
MR1O%-%(&4:64\^R^Z]C/>"ZMI[:;W&\:)U*F-[F]*N"/A;4A6AX&HIZXZ,+7
MWX]F[2Y@N8?;;P98W#"1+:Q#H0?B72X:J\10@^F>G;^8]T;WCU3\C^J?YTO\
MO6GD[,VIO+;&TMZ;^Q6W\;6YY7H:[:%+A/[Q9;;>.>/(9'KO?G7TD--EO`J5
M.*K(YJJ26%Y(YJ=CVUWS8MWY:W;V3]Q&^EO(9I(X2[!,B0MH5V[5FAFJT>KM
MD5M&:491[F[#OVS\S[1[X>W*_564\,<DP12^#&%ULB]S030T673W1NNLTK55
M,?\`A4)UI_H]^X7XI=@_Z6SCM`P!WIA/]'W\9,.C7_>D8O\`O&<?]UZO'_!Q
M(4]'DOZ_:;_@6-U^O_Y6N#]SUKK\&3QM/^D_LZT\_%T^?#'2G_@KMI_=]1RG
M<?OG331XT?@Z_P#3T\2E?+PM7EQSU)_E-?$SY-_)WYB[I_FN?-#`UNU:[(+E
M9^FMIY;%UF#J<ED,O@&V?CLSB-NY)WK<1UWLK8TKT.(-2&FR,\D-6DLAA>>H
MI[M\V\L<K<FVOM-R5<+*BE1<R*P<*%?Q&5G7M>:66CRZ>U%71BNE7/9_E'FG
MFOG2[]W>=[=H78,;:-E*%F9/#5UC;N2"&*J1:NYV;7FFI@@_X4I_#7)5V]^C
MOE?U]M^KR%;ONIHNB.P*3$4<E355N[(%J\EUGD?MJ9))JO(YS#K7XUY#8*N+
MHHENS@>S?[M'-\9L=]Y0O[@*MN&NXBQPL5`+D?()19?L,AZ)OO/<FR"_V'G'
M;[<L]R5LY@HRTM2;8_,O5XORC7J]CHC^7KL39'\MK$?`_=T:14NZ.H<GM[LS
M,XQ(:BI'9&]Z>7-[HW5C99;I65&V]Y5ODQ33%@D%!2H;H@'N"-^]Q=POO<N7
MGZS/ZD5XKP*:T$,1"QQGT#1BCT\V8\3U/NP>V^W6/MA%[?7H_3FLF2=EI4S2
M@M)(/4K*:I7R51P'6NA\=?F'\KOY$&\=U_%'Y2=*YKLWX_9+=>2W!U[NG;]5
M/CH"U:H6KW#U=N6OHJC";@PF?IJ2*>LP52]+54%86=VI9WJ8Y\D.8^3.4_?N
MSL^;.4]Z2VY@6)4EC<:B`.$=Q&IUJ\>5290R2)3!`!&-'+7.W-WW?KR]Y1YN
MV-[KEUIF>*1#I!)XR6\C#0R289X7*O&]<@DZE!\R?YU?<W\PC8&?^)WP7^./
M9^-;LG!Y*B[#S=1`NY>P,CL5*22;<F`Q&`VM#78W;>&R-!$\63R,]95>3'R2
MPA(-9D]I>3O9#9_;J_M^;>>^8[5OII%,*YCA$M:([-+I:1E8@I&J#NHQ)`IT
MJYS]\]Y]R-ON.3^0>6KI?JD99GQ),T5*NBK%J6-64$/(SGM)4`$UZ,9_PFZ[
M1ZXZN^'_`,JMP]C;ZVILK#;/[;H-T[HK]R9W'XJ+";>J-CXRGI,Q7BJG22*A
MKZK&5$-,]C]S/"\<6MQI]AS[R>S[KN?-_)]IM^W337,]D4C5$9B[^._:M!D@
M,"?0$$XST)?NR[SM.U\F\YW>X;E!!;07PDD9W50B>`@#-4B@)5@/4@@9%.BT
M)'O[_A0!_,3\D\>X]O\`P-^-U1Z8Y%K,6\VT9J_TQD7C-+V3WA78>[$:),5A
MZ6UY9,>/N1.ZV/W>O;G01&_/VYCY']0#C\X+0-CRDF;^%NT+HU_]XOW*U@R1
M^WVUGYC],G^4]V5SYQ0+_$.Y1?/SXK]E_P`GGY:[%_F!_";`RP]%;IST>#WS
MUECDK#MK:]=FVB&=ZVS5-3+420];=BPTOFQ4Q608G+1K'$(98,9Y$OM]S5M?
MO'RC?^WO.\]=^BC+Q3&FN0+73.I-/UX*TD'^BQ$DU_4(5>XG*>Z^R_..W^XO
M(UO3E^60)+`H.B,M37`X%:03@5C/^A3``4_3!V,NA?FIF_DKM7"[DZT^*OR,
MV[%EJ'&UD^2[NVWA^GMH4!K(D>H6GSF9S&2S^ZJ2F=BJU6#PV4IY=-]2_08X
M<P<D0\L7<]KNG->VR,C$!;60W,AIP[44(A/FLLJ$>G62O+O/,W--G;W>U<I;
MG&CJ"6NHUMHQ7CW.Q=P/)HHG!XUZ-\V`DW%@5Q>_:;#Y8U3))DL501UHP$RJ
M0RX^HAK)R^9H58?N+4(L51_:A4>D`[Z@6\YEL&=*<&--7V@@=I]*&H\F\^AI
M].;FW\*_5'K\2BN@_(@GN'K44/FOETIJ>G@I((*6E@AIJ6FACIZ:FIXTA@IX
M(46.&""&-5CBABC4*JJ`JJ``+>TK,SLSNQ+$U).22?,]*E545410$`H`,``<
M`!UF]ZZWU__5W^/?NO=>]^Z]U[W[KW26WAL;9/8>%J-M[_V?M;?.W:O_`(%8
M#>&W\3N;"U/X_P`HQ>:I*VAFX_U49]JK.^O=NG6YV^\E@N1P>-V1A]C*01^W
MI)>V%CN,#6VX644]L>*2(KJ?M5@0?V=`9@OB-TYL9I&ZDI=V])+)4"I.-ZFW
MON7:NT4D!)M'ULU?7]8HA)^G\&_P^GL^GYOWF^H-W:&^Q35<1)))_P`YJ"?_
M`*J=$,')VRV!)V=9K"IKIMY7CC_YP5,'_5+H:,+@MW8AS'5[XEW/1W`4[@V_
MB(<J$%A9J_;2;?Q[-8?7['D^R2>>TF%4L1$_]!V*_L?6?^-='<%O>0FCWYE3
M^FBAOVIH7_C'22SGQXZ`W/D9\ON7HWI[<.6JF+U.4SG6>RLMD:AR22T];7X2
MHJ96)-[LQ/M7!S#O]K&L-MOEY'$."K-(H'V`,!TDGY<Y>NI&FN=ALI)CQ9H(
MF)^TE2>F?_95_C#_`-XX]#?^B@Z^_P#L>]O?UIYG_P"FCO\`_LHE_P"@^F?Z
MJ<K_`/3-V'_9/#_T!T*FT]F;/V%AXMO;&VIMK9F`AFGJ(<'M/!8O;N'BJ*J0
MRU,\6,P]+1T4<U1*2TC!`SMR23[*KN]O+^8W%]=RS7!`&J1F=J#`&IB30>6<
M=&MI966WPBVL+2*"W!)"QHJ+4Y)TJ`*GSQGI*[MZ2Z8W_D?XQOOJ/K#>N6"+
M$,INW8.U=QY$1J`JQ_>YC$UE3H50`!JL`/:JTWO>;"/P;'=[J"'^&.61!^Q6
M`Z2W>Q[)N$OC7^SVL\W\4D4;M^UE)Z2O^RK_`!A_[QQZ&_\`10=??_8][5_U
MIYG_`.FCO_\`LHE_Z#Z2?U4Y7_Z9NP_[)X?^@.A;VSM7;&R\-2;<V=MS`[3V
M]0>04.!VUB,?@L-1":1IIA28O%T]+0TPEF=G;0BZF8D\D^RFZN[J]F>YO+F2
M:X;BSL68_:S$D_F>C>UM+6Q@2VLK:.&V7@B*$45SA5``SZ#I'_Z$^F1N7^^8
MZCZQ&\//]U_>O^X6U?[R_<ZM?W'\=_A/\4\^OG7Y=5^;^UG[[WKZ;Z/][W7T
M=*:/%DT4]-.K33Y4Z1_N/9/J?K?W/:_65KXGA1ZZ^NK3JK\Z]"=[*^C3IIS.
M`P6XJ>FI-P87$YVEHLECLS1TV9QM'DZ>DS&'JXZ_$96FAK89XX,EBZZ%)J:=
M`)8)4#HRL`?;T%Q<6S,]M.\;LK*2K%2584920156!(8<"#0XZ9GM[>Y54N8$
MD165@&4,`RG4K`$&C*0"IX@BHST[>V>GNF/<6V-M;OQ4^"W9M[![HPE5I-5A
MMQ8F@S>*J2M])GQ^2IZFDFTZC;4AM?V_;75S9RK/:7$D4XX,C%6'V%2#TQ<V
MMK>1-;WEM'+`>*NH93]H8$=-.SNNNONNZ6>@Z_V+LW8M#5.):FCV=MC";9I:
MB1;Z9)Z?"4-%#,ZZC8L"1?V[>;CN&XLK[A?S3N.!D=G(^PL33IFRVW;MM1H]
MNL(8$/$1HJ`_:%`Z0U9\:OCGD9\C4Y#H'I2NJ<O4"LRU16=5[%JI\I5BH:K%
M5D99\"\E;4"J=I=<I9O(2U[F_M>G,O,<:QK'O]ZJH**!/*`HI2@HV!3%!Y8Z
M0/RSRW(TK2<O6+,YJQ,$1+&M:M5,FN:GSSTOMG;`V)UWC9L-U_LK:6Q<145;
MU]1BMG;;P^V,;/721Q0O634.$HZ&EEJWAA1#(RERJ*+V`]E]YN%_N,BS;A>S
M3S`4#2.SD#C0%B32I..'1A9;?M^VQ-#MUC#;PEJE8T5%)X5(4`5H!GCTJ98H
MID\<T<<L>I&T2HLB:HW62-M+`C5'(@93^&`(Y]I02IJIH>E9`(H14=9/>NM]
M>]^Z]T5#N/XV[A[0[!Q^_,'V[G^NZC&8G;U)1Q87'U5;+'D=K[F7=>+J6$^X
M*;&28Z?*Q1?>TOVJK7P1F"I::)E6,5[/S);[7M\EA/M$=PK.Y.H@"CIX;#"%
MJA:Z6U=A.I:'B$MZY:N=UW"._@WB2V940#2"<H_B*<N%H6IJ73W@:6J.%?G_
M``SA5_\`>;WR>_\`0UWQ_P#;']C_`/UX4_Z8G;/^<<?_`%JZC[_6:?\`Z;?<
M_P#G)+_UNZ__UM_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M5H_-/^83M;X>_(7XD=6;TSFP-H]?]VR]L9?M;?V^3G&&Q]J;`VYCJO;QPJ86
MH4C+;PW1D100M/!4Q*4:Z*+NLG<D>W=USER[SANME;7,^XV(MUMXH='ZLLSD
M/KU#X8XE9SI(-:9\NHMYZ]Q[3DOF/DW:;ZYM8-MOC<-<2S:_THH8P4T:3\<D
MK*@U`BE<>?17]O\`\U?L'M?=.&7HW;O5.\.O^R/YANS_`(B]2;DJJ;>(J<]U
M3A]B+O7O'MJ:-<W0C)5&!I\ECCB3%#2TP2I83QRE+^Q7<^TNW;593-O-S>1;
MC:<MR;C=1_I@1W#3F&UMQ530/2LE26_A(Z"5K[O;ENU["NR6UG+MMWS-'MMI
M)^H3);K;B:[N#1A4IPCH`M/B!Z5/4'\R#O+N3KOX<;=VYUUUQ_LS/R0[F[?V
MYOW;X@W9+U_UATKT%V%NG;79W94T,>;DS<627$8W'P8FGK:V&GR&8JI(E?\`
M;$)2;O[9;)LNX<Z75YN-R.5]LL;:2)^P2SW5[!');P`Z-%*L[R$+58DKQ->E
MFS^Z&^;YMW)-I9;=:_UIW2_NHY4[S%!:V4\D=S.1KUU`5$C!:C3/3@*="15?
MS!-YT_QT[0[YQ>TML;LR/8WR5W7\>?@-U]AVK(J_NRKQV?\`]&.T,]N&OJ,L
ML<^/W)OK;>X<_/+3_P`/BI]IT4;!O,WD8JB]O+*7F3:M@EO)88;;;$O-UF;2
M1;*4\>14%!W)$\,*JQ8M<L5X8!M+[C7T7+.[<P0V44TUSNDEGM,*Z@;I@_@1
MLYJ>UY4FF9E"A;9=7')1FR_YD79^^^D_Y>&ZL/L?K^+M?Y<_(G(]3]G[8JO[
MP+A-D;,ZPS^^L3WKN#:\"9HY%<OMREVC'-1?>U-33(M1JE$B6/M?>^V>UV>]
M^Y5NU]<_N;9MM%S`YT!Y7G$/TBR=NFCF7NT@$T[2.B^Q]S]UO=B]LKE;&V_?
M6];FUM.@UF.)(#-]6\?=JJ@A[=9(%>X'H$]A?S,_F?7=9=3?,+>74_QOK?AG
MW!WW#U-AL?M?)]G8;Y"8+:N<[1S/6>W]^5U+GILGL?-1)68AYGIJ71-6*T91
M:>.1Y(#R]]KN2_WMO/)EAO&Y#G.RVPW+&183:-)';+<2PU73*E`2H8U`(H:G
MB167NKSO^Z-EYUO]FVQN2;W<Q;*(VF6[6*2Y:VBGHVJ)ZD!BHH2#BGDK\)_,
M7^3^]/EUOWIG:^)^+.#H^O?D57=/-\:.S,[O3K[Y1;_ZPQ.12DJN].O-V;MR
MN`ZRW'39G%Z\MC,-14-9)/C8GTSR'QR2))O;3E>RY.L-\NYMV<7&VBX^N@2.
M:PAN&4E;2:.-6F0A@(GD=T"N:Z=-1TLA]SN:KWG/<-BM(=H0VVYFW^@G>2&_
MFMU8*UY#)(RP."I,J1(CED%-6KJS/M?Y<]*=)[YS>P.Q\UEL!EMO=";V^264
MR#8.MJ,#%UEU]E:;#[EGAR<`<5>X*>MK81%CHD>IG\L80%I$5HOV?DW?M^L(
M=QVNW66*3<8;)5##69YU9HQIXZ2%:K_"*&O4I[SSKL&P;A-MNZW+131[;-?,
MQ4Z!;P,JR'5PU`LM$^(U%*]`QE/YD?1.$SVP\1F-F_(/$XS?,O3]!/O;*]';
MSQFQMC[@[WHL7D>LMJ;XW#D*:FCH-R9NDS5(:BGHHZ\8R6<0UK4\ZO&IU#[9
M[_<0;A+;WNW22P"Y81K=1-+*EIJ$\D2`DE%TMI9M'B!28PPH223>Y_+UM/M\
M5Q9;E'#<&U4RM:RK%$]YI^GCE<@4D?6NI5#^&6`D*FH'+'?S+_B]D.PLCLIZ
M_L7%[8H<IV+@*?O?,=9;LQ_QVS6X^I,1ELYV/@L-V_+1?W;JJG:V.P%:TE0Y
MCQ]2]*\=-43R%%;4WMAS7#MT=\8K=KIHX)#:K/&;Q8[EE6!VMZZP)"Z4&7`9
M2RJ#7K</NERG-N4E@);E;59)XQ=M!(+-Y+96:=$N2-!,81ZG"$HRJS$4Z"?=
M?\UWHJ;ISMG?FU8>QNOLSM7J[$=F]<Y+O+HCM#"[6['VKO/=N"Z]V+O_`&AB
ML?%C\_O?9.8WGNK&P"*DFH\E40U0DCC$8>1#>T]IM\3>MGL+Y[:XMY;QH)UM
M;NW:2%XD:6:*1B2D4BQHYU,&C!4@L2*=%%W[N["^R;S?V*75O<PV:SP-=VEP
MD<T<LBPPRQJ`'EC:5T&E2LA#`A0#7I;XS^9S\?*?LG!],;@'8]9O)N]J/XI;
MF[`V]U'O*/H^A^2#14]++L.#?E;]SCZ:IRF7%0M)2F>IJX*>G>:I$<"BH<OE
M]K^86VN?>X#:K9?N\WZ1/<1?5&SU$>+X0HQTBA8T4&HTU)ITOB]T^7%W6#8K
MA;MK[]X#;Y)DMI?I5O=(/A>,:J-1J%%6(H==!DY<#_-3^'V<W#D\;)N?>N`V
MC'A.V\_M/M_<?7>Z,9T_VGC^B,3DL]VZ_56]OLYX=['9.%PU953&GA$=5#2R
M&D:H](:MQ[4\X06T4PMH)+LO;I);I-&UQ`;I@MOX\5:Q^*S*HJ:J6`<+7JUO
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M[W[KW52N>_NQ_P`//8K_`$@?<>;_`(;PKO\`17_%_P"#_P!RO-_IY3^^WA^[
M_P`N_OOX/#]/V_X7J_-_<NV_U?\`K*3?N[X/ZQK]1IU:_P#<0^#PQX?Q_/7U
M#UQ]'_KX0?O+^T_JTWTVK3H_W+'CTKGQ/[/Y:.JQ?@U_<;_3=_+*_O3_`!S^
M]/\`IH_FB_QO5_"/X=_LS?D;^]'][/L?\FU_Z-?X=_!O%SY]5O<J\_\`U_[B
M]S_`\/POH-@T:==?W?H&C37_`(=_:ZO/AU$WM]]!^_O:WZCQ?$_>',.O5H_Y
M*'B=^NG_``C^QT^7'J-\%_[L?Q?^<%_H#_OA_LVW\%^27^RX_P!\/#]O_HF_
MTB]L>/\`T*?;^K[3_3-I_B-O\E_BW\+U^K[CWKG[ZKP?9G^L/@_U2K9?6^%7
M5X_@V]/J=7G])I\/_A?BT\NM^WWTGC>]?]7/'_K?2^^B\6FGP/&N*_2Z?+ZS
M5XG_``SPM7GT^]A_[)?_`'U^!O\`LSO^E/\`V1;_`&1K:O\`LF7]R_\`2=_#
MO]*7V^TO[]_WV_T!?\97_P!,O]U/L]?C_P!QNCS:_P#*_/[3;?\`UT_=O/\`
M_5?Z;^OG[^?]Y^)X.KZ>K^#X?U7Z'TWBZJU[M7AT[=/2G<?ZD?O/V\_K3]5_
M4#]P1_NOP_&T_443QO%^E_7^J\'32G9I\2O=JZ+AT7_=#Q]#?Z,_[^_W'_@O
M\Y[_`&1WS:_XI_'?]'\GD_B']X/]S?\`$O[M>;^'??\`^6_=^;S>KR^Q/S%]
M1HY@_>?TW[SU<L?O&E:>'7--/93Q-'B:>VFG1VTZ"W+?T^OEW]U_4_NS1S1^
M[:TKXFG%=7?7P]?AZNZNKQ.ZO3W\*/[^_P`"^!G^SV_Z7_\`9*_[][*_V3/^
M[?\`H._T(?Z7=6;_`-'7^G;_`$=_\9+_`(Q_&/N?L?XMZ?XI?[C]K[[VWSU]
M+]9[D_U&^A_KWX<W[RU_5?5?3U'U'T?C?H:-.GQ/#[O"^'%.G>0_J_H_;+^O
M?UW]0?%A_=FCZ7Z3ZFA^G^M\']?7JKX?B=OC?'FO3[LW_3Q_IM^"W^SE?Z9/
M]D]_V;[!?[)Y_IE_N'_L[W^D;^]&6_T.?Z=OXU_QF+_1C_>/[O[S1Q]A]G]Q
M^Q]E[1WW]7?W#SY_4OZ/^N7[F/[Q^F\;]U^#HC^H^DT_XO\`4:?XNW7XGA]U
M>EMC_63^L'(']=OK?ZE_OH?N[ZGP/WIXVN7Z?ZO5_C'T^JOP]VCP_$[:='<_
MFY?Z%?\`9Q_Y?7^FK^^G^C6V_O\`3C_=_P"R_N=_HG_TG]"_P'_2[]Q^[_HQ
M_P!*W\)_BO\`NK['SW]>CV!_:#]]_P!2O<;]R^!^\:0_2Z]7B?4^#=:OIZ8^
MH^F\;PZYU4IGH=>\G[C_`*[^VW[[\?\`=M9OJM&GP_IO&M-/U-<_3_4^#XM,
M::UQU7QV#X_^''J3_39_#_[K_P##LVQ_[E?Z4OX+_LR_A^^I_P"Z'\-_C/\`
MN1_V3?\`CGV7]T_[O_Y)X[_Q3]_P>Q_MW_3MG_<NKZO^J,OB>#K^CK7]2NCM
M_>.C7]1X^?\`?6.H^W*O^N9'^^]/T?\`7"+P_'T?6TI^G\?=^[=>CZ?P,?[]
MSTLNA?\`29_LH79W]]?]/_\`PUQ_H+^;?^@#_1Q_HW_O[]A_'.Q/[P?[,QJ_
M>_O%_>#^(?W0T_[C_P")Z?XE^UJ]L;S^Z_ZX[-^ZOW=_KL?O':OJ?&\?PM>F
M+1]%7M\.GA_5:N_3_88KT]LO[U_J9O7[V_>7^M'^[=V^E\#Z?Q=&N77]=3N\
M2OB?2Z>S5_;YZ$&/_9MO]!'2O^SP?WR_T;_Z?_Y=7\,_@'^CK_0)_LNO]]<;
M_#O+_=O_`"K_`$J_WJ_A/][/NOVOM/%_#?\`)[>T"_U1_?N\?U!^G_>7[NWK
M5XGC?6?5_3G7\?;]/X?B_2Z>[7J\;NIT8-_7#]P[-_KA?4_NO]Y;'I\/P/H_
MI/J!H^#N^H\7POJ]?;HT^#VUZ5W4W]T_X'\$_P#23_%/MO\`AS[YK?Z>?N/X
M;Y/]FE\7<_\`='^)?;?N?=?;Z_M/#^_?1;U6]I-Y^L\?W!_=_@Z_ZI;5]+35
M_N#_`(GKT5\^'B:NWX^EFS?1^![>?O#Q_#_K?NWU==/^YW^.Z-=/P\?#IW?!
MT17X1?W+\.8_N/\`Z*/O_P#9?>[O]DZ_T;?[)'_LT7\1U9R_^S/?WH_W)_W^
M_P!%OW_GT_[A?[N?Q#^(?NZ?8YYW^I\6']X_4:?WI:_O+Q_WG]!2HK]#X/;]
M/X^GA^MXWA>#VUZ`?(OTOA3_`+M^FU?NN[_=?@?NOZ^M#3Z_QL_4>!KX_H^#
MXOC]U.K;/Y(7@_BGS*\O]S_X[_?;J/\`CW^RX?:?[(W]W_<7(V_V77^&_P"X
MK^^FK7_?S[3_`"3^(?9?;?Y-X?<0>^?BZ>3-7U'A?3SZ/K:_O33XHI]9J[O#
MI3Z75W:->KNKU,?L/X6OG;3]/XWU,&OZ&G[JU>$:_1Z>WQ:U^KT]OB:-/;3J
1^_W`'60O7O?NO=>]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
